Bharat Biotech's Covid-19 nasal vaccine to cost ₹800 in pvt market, ₹325 for govt supplies
The iNCOVACC vaccine received Indian drug regulator's approval to be used as a booster dose for the adult population.
The iNCOVACC vaccine received Indian drug regulator's approval to be used as a booster dose for the adult population.
The vaccine will be available on the Co-WIN platform for persons aged above 18 years for primary 2 dose schedule, homologous booster doses, from Friday evening.
It’s India's first nasal vaccine against Covid-19. Health minister Mansukh Mandaviya says it’ll further strengthen country's fight against pandemic
Hyderabad-based Biological E Limited (BE), which recently launched its indigenously made Covid-19 vaccine Corbevax, will focus on new vaccines, specialty injectables, and branded generics.
The funding seeks to establish preclinical and clinical proof of concept for a vaccine designed to provide protection against all known SARS-CoV-2 variants.
India has learned a lot and is in a stronger and better position to face any future wave or future pandemics, says Adar Poonawalla.
Technology Development Board and Bharat Biotech will put in ₹200 crore each to create a continuous corpus of ₹400 crore for the partnership project.
India should review its vaccine policy to favour the safest vaccine of all the vaccines that have been approved for the coronavirus, says expert.
The industry body has urged the central government to raise the CSR levy by an additional 1% for a period of 12 months to provide Covid-19 booster vaccines to the community.
While 65.65 crore Indians have taken both the doses, first dose has been taken by 91.08 crore people.